Achieve announces completion of target enrollment in the phase 3 orca-3 trial of cytisinicline for smoking cessation

Orca-3 designed to enable fda registration and confirm the efficacy and safety of 3 mg cytisinicline three times daily dosing compared to placebo in adult smokers in the united states orca-3 designed to enable fda registration and confirm the efficacy and safety of 3 mg cytisinicline three times daily dosing compared to placebo in adult smokers in the united states
ACHV Ratings Summary
ACHV Quant Ranking